[{"id":"8ce2ca4d-2661-4482-8916-b26986676394","acronym":"IMPACT","url":"https://clinicaltrials.gov/study/NCT05353530","created_at":"2022-04-29T11:55:39.775Z","updated_at":"2024-07-02T16:35:17.387Z","phase":"Phase 1","brief_title":"Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT)","source_id_and_acronym":"NCT05353530 - IMPACT","lead_sponsor":"University of Florida","biomarkers":" MGMT • CD70","pipe":" | ","alterations":" CD70 expression","tags":["MGMT • CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 8R-70CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/25/2023","start_date":" 07/25/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2042","study_completion_date":" 12/01/2042","last_update_posted":"2024-02-28"},{"id":"aea53f71-450f-4f70-b26a-ec60ce665fd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010875","created_at":"2023-08-25T15:08:21.321Z","updated_at":"2024-07-02T16:35:29.927Z","phase":"Phase 1","brief_title":"A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT06010875","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD70","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2023-11-08"},{"id":"b39d06d8-a44b-42df-b66d-73b2afe00351","acronym":"","url":"https://clinicaltrials.gov/study/NCT05518253","created_at":"2022-08-26T11:59:07.710Z","updated_at":"2024-07-02T16:35:39.465Z","phase":"Phase 1","brief_title":"A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05518253","lead_sponsor":"Weijia Fang, MD","biomarkers":" IL6 • CD70","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2023-08-21"},{"id":"041b80da-d322-4251-85ad-bc74493b1b44","acronym":"","url":"https://clinicaltrials.gov/study/NCT05468190","created_at":"2022-07-21T12:57:30.700Z","updated_at":"2024-07-02T16:35:39.664Z","phase":"Phase 1","brief_title":"A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T","source_id_and_acronym":"NCT05468190","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD70","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/17/2022","start_date":" 07/17/2022","primary_txt":" Primary completion: 07/17/2024","primary_completion_date":" 07/17/2024","study_txt":" Completion: 07/17/2025","study_completion_date":" 07/17/2025","last_update_posted":"2023-08-17"},{"id":"74723d01-6fac-468b-9d9a-0098ac086d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420545","created_at":"2022-06-15T15:55:30.045Z","updated_at":"2024-07-02T16:35:39.690Z","phase":"Phase 1","brief_title":"A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05420545","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD70","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-17"},{"id":"abdbe93e-0aca-4bb6-a38b-acf7dc98d6fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420519","created_at":"2022-06-15T15:55:29.531Z","updated_at":"2024-07-02T16:35:39.788Z","phase":"Phase 1","brief_title":"Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer","source_id_and_acronym":"NCT05420519","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD70","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-17"},{"id":"c403aee5-2a23-4596-8765-c6e6713663ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05948033","created_at":"2023-07-17T14:08:48.088Z","updated_at":"2024-07-02T16:35:42.783Z","phase":"Phase 1/2","brief_title":"CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma","source_id_and_acronym":"NCT05948033","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" IL6 • TNFA • CD70 • IL2 • IL10","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • TNFA • CD70 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • UCL70802"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/15/2023","start_date":" 07/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-07-17"},{"id":"d6d66642-1f53-4555-8490-4700bdf032dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05947487","created_at":"2023-07-17T14:08:40.998Z","updated_at":"2024-07-02T16:35:42.879Z","phase":"Phase 1/2","brief_title":"CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05947487","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" IL6 • TNFA • CD70 • IL2 • IL10","pipe":" | ","alterations":" CD70 expression","tags":["IL6 • TNFA • CD70 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD70 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • UCL70802"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/15/2023","start_date":" 07/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-07-17"}]